NCT01359020

Brief Summary

The purpose of this study was to compare the efficacy and tolerability of acetaminophen, dipyrone and ibuprofen to fever control in children. For the efficacy asses were compared:

  • the time to start the action;
  • the action duration;
  • the difference between the basal temperature and the lower temperature in the study period. For the tolerability asses all adverse events were recorded, as well as your intensity and the relation to the treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
396

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Jan 2007

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2007

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2008

Completed
3.2 years until next milestone

First Submitted

Initial submission to the registry

May 20, 2011

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 24, 2011

Completed
Last Updated

May 24, 2011

Status Verified

May 1, 2011

Enrollment Period

1.2 years

First QC Date

May 20, 2011

Last Update Submit

May 23, 2011

Conditions

Keywords

FeverIbuprofenAcetaminophenDipyrone

Outcome Measures

Primary Outcomes (1)

  • Antipyretic efficacy

    The antipyretic efficacy was assessed comparing the time to the beggining of the action of the drugs, the difference between the final and inicial temperature and time of action.

    Temperature was verified 15, 30, 45 and 60 minutes, 2, 3, 4, 5, 6, 7 and 8 hours after the administration of the drug.

Secondary Outcomes (1)

  • Adverse Events

    Adverse Events were verified at 15, 30, 45 and 60 minutes, 2, 3, 4, 5, 6, 7 and 8 hours after the administration of the drug.

Study Arms (3)

Ibuprofen

EXPERIMENTAL

10 milligram per kilo, oral administration

Drug: ibuprofen, dipyrone, acetaminophen

Acetaminophen

ACTIVE COMPARATOR

10 milligram per kilo, oral administration

Drug: ibuprofen, dipyrone, acetaminophen

Dipyrone

ACTIVE COMPARATOR

10 milligram per kilo, oral administration

Drug: ibuprofen, dipyrone, acetaminophen

Interventions

The dosage for the three drugs was the same: 10 milligrams per kilo, oral administration

AcetaminophenDipyroneIbuprofen

Eligibility Criteria

Age6 Months - 6 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • male and female children aged 06 months to 06 years old, weight above 5 kilo and axillary temperature above 37,5 celsius degree.

You may not qualify if:

  • patients with a bad general heath state
  • patients with neoplasia, pepic ulcer, gastrointestinal bleeding,history of fever convulsion;
  • intolerant to dypirone, ibuprofen, acetaminophen or any other nonsteroidal antiinflammatory drug;
  • moderated or severe dehydration;
  • conscience state alteration;
  • not capable of ingest oral drugs;
  • patients being treated with steroids;
  • patients treated with antiinflammatory, analgesic and antipyretic drugs in the last 06 hours before the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Instituto de Medicina Integral Professor Fernando Figueira

Recife, Pernambuco, 50070-550, Brazil

Location

MeSH Terms

Conditions

Fever

Interventions

IbuprofenDipyroneAcetaminophen

Condition Hierarchy (Ancestors)

Body Temperature ChangesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PhenylpropionatesAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsAminopyrinePyrazolonesPyrazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsAcetanilidesAnilidesAmidesAniline CompoundsAmines

Study Officials

  • Claudia Patrícia DN Moura

    Mantecorp Indústria Química e Farmacêutica Ltda.

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

May 20, 2011

First Posted

May 24, 2011

Study Start

January 1, 2007

Primary Completion

March 1, 2008

Study Completion

March 1, 2008

Last Updated

May 24, 2011

Record last verified: 2011-05

Locations